UnknownPhase 1/2

Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration

United States45 participantsStarted 2022-11-17

Plain-language summary

This safety study comprises a dose escalation study of VOY-101, followed by a cohort of subjects randomized to the maximum tolerated dose arm, a lower dose arm, and control arm.

Who can participate

Age range50 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Are ≥50 years of age at the time of consent.
✓. Are willing and able to understand and provide written informed consent.
✓. Are willing and able to return for scheduled treatment and follow-up examinations.
✓. Are able to undergo ETDRS BCDVA testing and ophthalmic imaging.
✓. Well-demarcated GA secondary to AMD in the absence of MNV and in the absence of history of MNV.
✓. Absence of signs of non-exudative MNV.
✓. Additional Ocular Inclusion Criteria
✓. Meet certain genotype criteria for risk of AMD.

Exclusion criteria

✕. Are women of childbearing potential (WOCBP) and are pregnant or unwilling to use and document use of effective contraception for the duration of the study.
✕. Additional Systemic, Ocular, and Genetic Exclusion Criteria.

What they're measuring

Safety Endpoints

Timeframe: Through 24 months

Trial details

NCT IDNCT05380492

SponsorPerceive Biotherapeutics, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-11

View on ClinicalTrials.gov More Age-related Macular Degeneration trials